Riskpilot← Back to searchSign inGet full accessAlanoar-medicin AB
ABActiveOrg 5591416630Haleniigatan 5Hospital activities · NACE 8610Est. 20171 employees
Revenue 2025
SEK 508K
-58% vs 2024
EBITDA margin
59.4%
-68% vs 2024
Equity ratio
97.3%
Financial strength
Net profit 2025
SEK 305K
-63% vs 2024
| Revenue | SEK 508K | -58% |
| EBITDA | SEK 302K | -68% |
| Net profit | SEK 305K | -63% |
| Total assets | SEK 6,2M | -12% |
| Equity | SEK 6M | +2% |
| Employees | 1 | — |
Legal name
Alanoar-medicin AB
Org number
5591416630
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
21 december 2017
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Man ska hyra tjänster inom medicin till olika landsting i Sverige
Address
Haleniigatan 5
Email
drdia1@yahoo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 364 | 1 076 | 4 108 | 1 196 | 508 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 260 | 834 | 3 600 | 937 | 302 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 260 | 834 | 3 600 | 937 | 302 |
| Net financials | −2 | — | 929 | 101 | 81 |
| Profit before tax | 259 | 834 | 4 529 | 1 038 | 383 |
| Tax | −54 | −172 | −748 | −212 | −78 |
| Net profit | 205 | 662 | 3 781 | 826 | 305 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 435 | 2 079 | 7 020 | 7 005 | 6 162 |
| Equity | 1 217 | 1 691 | 5 278 | 5 904 | 5 994 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 218 | 387 | 1 743 | 1 102 | 167 |
| Total debt | 218 | 387 | 1 743 | 1 102 | 167 |
EBITDA margin
59.4%
This company
15.8%
Market median
+276% vs market
20212025
Equity ratio
97.3%
This company
38.2%
Market median
+155% vs market
20212025
Return on equity
5.1%
This company
18.4%
Market median
-72% vs market
20212025
Net profit margin
60.0%
This company
8.1%
Market median
+641% vs market
20212025
Asset turnover
0.08×
This company
1.12×
Market median
-93% vs market
20212025
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Alanoar-medicin AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anoar Karim Jabr | Deputy Board Member | 0 companies |
| Dhiaa Kadhem Saleh | Board of Directors | 0 companies |